Catalyst

Slingshot members are tracking this event:

Inovio Pharma (INO) plans to advance INO-3112 vaccine in combination with MedImmune’s immuno-oncology molecules into a Phase 1 study of HPV-related cancers in 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
INO

100%

Additional Information

Management Comment "Thought leaders have suggested that such combinations represent an important avenue to take patients’ response-rate beyond the 20% to 40%, typically achieved by checkpoint inhibitors used as monotherapy. We are talking about powerful one to punch"
-CEO Joseph Kim
http://seekingalpha....
Additional Relevant Details Completed enrollment of 22 subjects in the phase I study of our HPV-driven cancer immunotherapy, INO-3112, in head & neck cancer patients. We expect to report additional immune response and safety data in 4Q 2016.
http://ir.inovio.com...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ino-3112, Phase 1 Trial, Hpv Infections, Cancer  immunotherapy